David N. O’Neal

Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men

Trevor A. Mori, Valerie Burke, Ian B. Puddey et al. · American Journal of Clinical Nutrition · 2000 · 585 citations

Metabolic Syndrome, Purified Eicosapentaenoic, Diabetes +8

Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice

Moshe Phillip, Revital Nimri, Richard M. Bergenstal et al. · Endocrine Reviews · 2022 · 364 citations · Full text

Biomedical Engineering, Artificial Pancreas, Aid Systems +16

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

John R. Petrie, Nish Chaturvedi, Ian Ford et al. · The Lancet Diabetes & Endocrinology · 2017 · 337 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +7

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial

Paresh Dandona, Chantal Mathieu, Moshe Phillip et al. · The Lancet Diabetes & Endocrinology · 2017 · 286 citations · Full text

Metabolic Syndrome, Type 1, Diabetes Management +9

A Glycemia Risk Index (GRI) of Hypoglycemia and Hyperglycemia for Continuous Glucose Monitoring Validated by Clinician Ratings

David C. Klonoff, Jing Wang, David Rodbard et al. · Journal of Diabetes Science and Technology · 2022 · 254 citations · Full text